Gürman G, Celebi H, Ustün C, Arat M, Ilhan O, Ozcan M, Arslan O, Uysal A, Akan H, Beksaç M, Konuk N, Koç H
Department of Hematology, Ankara University Medical School, Ibn-i Sina Hospital, Turkey.
Ther Apher. 2001 Feb;5(1):54-7. doi: 10.1046/j.1526-0968.2001.005001054.x.
Allogeneic peripheral blood stem cell transplantation (PBSCT) is rarely applied for the treatment of severe aplastic anemia (SAA) because of questionable durability of engraftment and increased risk of graft versus host disease (GVHD). We performed allogeneic PBSCT in 3 SAA patients from their human leukocyte antigen (HLA)-identical siblings. One received bone marrow after conditioning with cyclophoshamide (Cy) plus antithymocyte globulin. He had a second transplant with peripheral blood stem cells from the original donor because of a graft failure (GF). Two other patients received PBSCT as a first option, with Cy as the only conditioning drug. The 3 patients received short-term methotrexate and cyclosporine as a postgrafting immunosupression. In the latter 2 cases, no GF has been observed, and a successful and complete hematological recovery was achieved and maintained for 28 and 25 months, respectively. In conclusion, PBSCT provides a quick and complete hematological recovery in SAA patients.
由于植入的持久性存在疑问且移植物抗宿主病（GVHD）风险增加，异基因外周血干细胞移植（PBSCT）很少用于治疗重型再生障碍性贫血（SAA）。我们对3例SAA患者进行了来自其人类白细胞抗原（HLA）相同同胞的异基因PBSCT。1例在接受环磷酰胺（Cy）加抗胸腺细胞球蛋白预处理后接受了骨髓移植。由于移植失败（GF），他接受了来自原供体的外周血干细胞的第二次移植。另外2例患者将PBSCT作为首选，仅使用Cy作为预处理药物。这3例患者在移植后接受了短期甲氨蝶呤和环孢素作为免疫抑制治疗。在后2例中，未观察到GF，分别成功且完全地实现了血液学恢复，并分别维持了28个月和25个月。总之，PBSCT可使SAA患者快速且完全地实现血液学恢复。
